IQVIA Holdings Inc. (NYSE:IQV) Stock Has Average Target Price of $294.21 According to Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been given an average rating of “Moderate Buy” by the twenty-one ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $294.21.

A number of research analysts have issued reports on the stock. Weiss Ratings downgraded shares of IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a research report on Wednesday, October 28th. BMO Capital Markets raised their target price on shares of IQVIA from $270.00 to $305.00 in a research report on Monday, October 19th. UBS Group initiated coverage on shares of IQVIA in a research note on Wednesday, September 30th. They set a “buy” rating and a $345.00 target price on the stock. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, TD Cowen increased their price target on shares of IQVIA from $288.00 to $307.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th.

Insider Activity at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.70% of the stock is currently owned by insiders.

Institutional Trading of IQVIA

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of IQVIA in the 2nd quarter worth about $2,811,292,000. Canada Pension Plan Investment Board purchased a new position in IQVIA during the 2nd quarter valued at about $240,911,000. Bank of America Corp DE bought a new stake in IQVIA during the second quarter worth about $235,551,000. Legal & General Group Plc bought a new stake in IQVIA during the second quarter worth about $211,342,000. Finally, Bank of New York Mellon Corp purchased a new stake in IQVIA in the second quarter worth about $180,296,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQV stock opened at $278.84 on Friday. The firm has a market cap of $45.95 billion, a P/E ratio of 22.78, a P/E/G ratio of 2.34 and a beta of 1.16. IQVIA has a fifty-two week low of $154.50 and a fifty-two week high of $284.50. The business’s 50 day moving average price is $266.92 and its 200-day moving average price is $211.22. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The company had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter in the prior year, the company earned $3.00 earnings per share. The firm’s revenue for the quarter was up 8.0% on a year-over-year basis. On average, equities research analysts anticipate that IQVIA will post 11.53 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products.

The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.